The Ferryman

Computer-based Predictive Toxicology: Advances and Impact of Cheminformatics on the Safety-oriented Design of New Products

Current advances in computer-based predictive toxicology offer the potential to create more advanced environments for the screening and prediction of safety issues due to chemical and drug adverse side effects, drug-drug and chemical-system interactions, and chemical and drug toxicologies in the environment and the human body.  Advances in this growing field also offer the potential to replace or reduce the need for animal testing and to reduce later stage clinical trial failures or new product development rejection. Acceleration of progress in practical applications requires the creation of interoperable environments, knowledge sharing, data integration, algorithm development, and extensive validation and testing. 

Numerous opportunities exist in this field for scientific advances, but also for innovation, service and product development, and value creation. Additionally, significant collaboration approaches are a scientific, industry and society imperative to advance this field and the safety of new products and all society members.  Collaborative approaches need to support the multidisciplinary networking and collaboration between computer scientists, biologists, chemists, toxicologists, product development and clinical and environmental researchers, and to network groups, centers, initiatives, projects and data into interoperable semantic frameworks, systems, knowledge bases and virtual organisations.

At our Predictive Toxicology session chaired by Artem Cherkasov (University of British Columbia) running 17 October 2008 at Bryn Mawr recent developments in the field of predictive toxicology will be presented and discussed.

The session will be preceded the evening of October 16 by a Knowledge Café to discuss Collaboration Opportunities in Predictive ADME & Predictive Toxicology.

A description of the session with presentation abstracts follows.  Please add your comments, discussion or questions at the end of the post.

Predictive Toxicology

http://innovationwell.net/COMTY_confprogr08predtox

(Please follow continuation here to read abstracts.  Comments can be made at the end.)

InnovationWell Membership & Workshop Activity for 2007

During November I will be planning the program for the following InnovationWell workshop in Oxford (cross-industry sector) and InterAction Meeting in Bryn Mawr (life science/pharma/healthcare sector). Please contact me with your interests and proposals!

Knowledge Assessment & Performance Improvement of Collaborative Work and Innovation Activities
InnovationWell Workshop & Innovation Café, accompanied by pre-meeting
2 day hands-on workshop activities on collaborative systems and ELNs
20-22 June 2007, Oxford University, Oxford UK

Innovation in Life Science & Healthcare Research & Product Development
InnovationWell Community of Practice InterAction Meeting
15-18 October 2007, Bryn Mawr College, Philadelphia, PA, USA
Themes: FDA Critical Path Themes, Knowledge Management, Translational Research, Biomedical Informatics, Metabolomics, Biomarkers, Toxicology, Patient & Drug Safety

InnovationWell Gold membership
This entitles members to access InnovationWell meeting proceedings including audio, access to our Executive Insights reports from meeting and community of practice activities, and additional member discounts on meeting and training registration fees.

Download InnovationWell2007MembershipForm.pdf

Barry Hardy

Email: barry.hardy *[at]* douglasconnect.com

InnovationWell meeting workshop conference management executive Bryn Mawr Philadelphia Critical Pathbiomarkers metabolomics toxicology personalised medicine KM Life Sciences Pharma Drug Discovery Drug Safety Research and Development Drug Development Healthcare Innovation Knowledge Management events

InnovationWell Interest List and Signup

You can join our InnovationWell interest list (managed by Constant Contact) to be kept posted on news related to our community of practice activities using the following signup form:

Join Our Mailing List

Email:

Barry Hardy

InnovationWell Community of Practice

European InnovationWell InterAction Meeting Final Program (9,10 November 2005)

The European InnovationWell InterAction Meeting "Knowledge-based Innovation in Life Science Product Development" takes place in Basel, Switzerland next week (November 9-10).  The schedule with list of presentations and discussion sessions is available at:
http://echeminfo.colayer.net/files/SpeakerTopcSchedule-IA05-Basel-v5.pdf

Included in the meeting will be a one day session running November 9 on Knowledge Management in R&D with further details being made available at:
http://innovationwell.net/COMTY_randd

The eCheminfo Drug Discovery meeting runs concurrently with our InnovationWell Community meeting; registrants are welcome to attend sessions from either program.  Further details, such as abstracts and speaker bios, can be viewed in the Program areas of either the innovationwell.net or the echeminfo.com websites.

We will be closing registrations shortly, so please let us know quickly if you'd like to come.  Register through the websites or contact Nicki Douglas (nicki.douglas at douglasconnect.com, +41 61 851 04 61)

And if you can't make the meeting, you can access the recordings and presentation materials if you become a member of one of these communities. You will also have access to all previous sessions (including those from last month's US InterAction meetings in Philadelphia being released this month which also included a 1 day Knowledge Management in R&D program).

Barry Hardy
Community of Practice Manager
Douglas Connect, Switzerland
tel: +41 61 851 0170

InnovationWell meeting workshop conference management executive drug safety KM Life Sciences Pharma Drug Discovery Research and Development Drug Development Healthcare Innovation Knowledge Management events

Program for InnovationWell & eCheminfo InterAction Meetings

I summarise below the list of sessions with over 100 top speakers and discussion leaders for the program listing for the upcoming Autumn InterAction Meetings taking place in Philadelphia and Basel. Please add a traceback or link for other like-minded folk to find!

I also provide an electronic brochure for download here for the InnovationWell Autumn Program on Knowledge-based Innovation in Life Science Product Development:

Download InnovationWell-ProgramAutumn05.PDF

And the equivalent eCheminfo brochure on Drug Discovery:

Download eCheminfo-ProgramAutumn05.pdf

Note: The poster sessions will be run as electronic poster sessions using tabletop spaces, a wireless network and Internet facilities at the meetings, in addition to virtual access through the website, i.e., the posters will be electronic but the access can be face-to-face or virtual. You can participate in person and virtually in the poster sessions.  We can supply nourishment and refreshments locally; remote participants may have to order out! [We also expect, subject to on-site testing, to have live conference call capabilities for remote participating members to join local discussions.]  Anyone interested in presenting such an "electronic poster" should directly contact us via email at innovationwell at douglasconnect.com

Look forward to seeing you in Philadelphia or Basel!

Barry Hardy
Community of Practice Manager
Douglas Connect
http://douglasconnect.com/
+41 61 851 0170 (office)

InnovationWell & eCheminfo InterAction Meetings
Philadelphia, US, 11-12 October 2005 and Basel, Switzerland, 9-10 November
List of Sessions with Speakers & Schedule (InterAction Autumn Meetings)
http://innovationwell.net/ and http://echeminfo.com/

Registration to attend the meetings or to access virtually is available through the websites or through contacting Nicki Douglas [nicki.douglas at douglasconnect.com]

InnovationWell eCheminfo meeting workshop conference management executive drug safety KM Life Sciences Pharma Drug Discovery Drug Development Healthcare Innovation Informatics Knowledge Management events

…PROGRAM LISTING CONTINUING IN FULL POSTING…..

Knowledge-based Intellectual Property Management, Auditing and Investment in the Life Sciences

Value is constantly being created in a life science or healthcare company through intellectual property creation, but additionally through tacit knowledge growth and intellectual capital utilisation, and through innovation-generating knowledge networks leading to action and outcomes. Additionally, technology licensing, out-sourcing and in-sourcing of strategic partners, and acquisitions bring new knowledge and intellectual property opportunities to the organisation.

Techniques such as knowledge audits, inventories and maps can be used to capture the current state of knowledge in an organisation and to identify strengths, weaknesses and gaps. Such analysis accompanied by the selection of appropriate metrics can be used to guide knowledge management strategies and planning. Finally, any proposed knowledge-based initiative needs to be supported by a sound financial analysis, clearly demonstrate investment returns and measurable tangible benefits, clarify intangible benefits that can be understood and tracked, and include a weighting of risks and most probable outcomes in the marketplace.

The goal of this program is to enhance the appreciation, understanding and best practice in life science and healthcare knowledge management so as to maximise the effectiveness, protection and value of organisational intellectual property assets. Questions addressed by this program include:

How do we increase innovation, value and returns from product life cycle and intellectual property management of life science product related knowledge?

How do we manage and value drug-related knowledge that is captured in ontologies?

What are the best practices in knowledge audits, inventories and maps applied to life science product development? What are the challenges requiring methodology development?

What are the appropriate financial analysis tools for evaluating an investment decision in a knowledge management initiative in a life science or pharmaceutical company?

How should drug safety, uncertainty and risk management issues be included in the financial analysis?

What steps should an organisation take to improve its performance in corporate sustainability as measured by knowledge management, organisational learning and human capital assessment metrics?

What is the impact of these metrics and the improvement by an organisation in areas of weakness on sustainability indices and the valuation of a company?

How do we value tacit knowledge and intellectual capital in a pharmaceutical company?

What are the current legal guidelines, practical experiences, law/legal case studies relating to use/acceptance (or not) of electronic records and submissions?

What are the best practices for legal and intellectual property protection in collaborative knowledge management systems and electronic notebook systems?

How do we better manage intellectual property of healthcare product and associated safety knowledge?

How should we publish and manage delivery of new drug knowledge to partners, payors, providers and patients?

What is the potential impact of new regulatory initiatives, e.g. FDA SPL and e-labeling? What are the impacts of new European regulations?

What new approaches for managing knowledge are being created by the increasingly electronic and semantic nature of information capture, management and collaboration? What are the legal and regulatory risks and how do we manage them?

How can existing knowledge and intellectual property be more effectively deployed into new business situations?

We will be exploring some of these questions with a leading panel of financial, investment and regulatory experts at our European InnovationWell meeting in Switzerland in November:

InterAction Meeting Session, Basel, Switzerland, 10 November 2005
chaired by Ronald Layden (Venture Valuation AG)

Presenters & Discussion Leaders:
Dr. Ronald Layden, Senior VP Technology, Venture Valuation
Dr. Rudolf Gygax, Managing Director, Novartis Venture Fund
Dr. Gerard Farmer, Partner and Regulatory Expert, Alfomec International Regulatory Consultants
VP Business Development, Pharma
Dr. Antonino Cattaneo, CEO, Lay Line Genomics
Dr. Stefan Odenthal, Partner, Arthur D. Little

Further information can be found at InnovationWell

Barry Hardy
InnovationWell Community of Practice Manager
Douglas Connect, Switzerland